Changes in epidermal growth factor receptor expression during chemotherapy in non-small cell lung cancer

Cancer Chemotherapy and Pharmacology

Volumn 73, Issue 1, 2014, Pages 131-137

  Jakobsen, Jan Nyrop ^a   Santoni Rugiu, Eric ^a   Sørensen, Jens Benn ^a  

^a University of Copenhagen   (Denmark)

Author keywords

Biomarker; Chemotherapy; EGFR; Heterogeneity; NSCLC

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; PACLITAXEL;

ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL;

EID: 84892803927     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2329-0     Document Type: Article

References (24)

1. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TPJ, Leahy DJ, et al. (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12(3):541-552
2. Pérez-Soler R (2004) HER1/EGFR targeting: refining the strategy. Oncologist 9(1):58-67
3. Yarden Y (2001) The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37(Suppl 4):S3-S8
4. Wolff AC, Hammond MEH, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. (2007) American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25(1):118-145
5. Nicholson RI, Gee JM, Harper ME (2001) EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4):S9-15
6. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357(20):2040-2048
7. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, et al. (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626-1634
8. Pirker R, Pereira JR, von Pawel J, Krzakowski M, Ramlau R, Park K, et al. (2012) EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol 13(1):33-42
9. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. (2009) Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361(10):947-957
10. Jakobsen J, Santoni-Rugiu E, Ravn J, Sorensen J (2013) Intratumor variation of biomarker expression by immunohistochemistry in resectable non-small cell lung cancer. Eur J Cancer. doi: 10.1016/j.ejca.2013.04.003
11. Meert AP, Martin B, Verdebout JM, Paesmans M, Berghmans T, Ninane V, et al. (2004) Correlation of different markers (p53, EGF-R, c-erbB-2, Ki-67) expression in the diagnostic biopsies and the corresponding resected tumors in non-small cell lung cancer. Lung Cancer 44(3):295-301
12. Taillade L, Penault-Llorca F, Boulet T, Fouret P, Michiels S, Taranchon E, et al. (2007) Immunohistochemical expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol 18(6):1043-1050
13. Grob TJ, Hoenig T, Clauditz TS, Atanackovic D, Koenig AM, Vashist YK, et al. (2013) Frequent intratumoral heterogeneity of EGFR gene copy gain in non-small cell lung cancer. Lung Cancer 79(3):221-227
14. Pápay J, Sápi Z, Egri G, Gyulai M, Szende B, Losonczy G, et al. (2009) Platinum-based chemotherapy in lung cancer affects the expression of certain biomarkers including ERCC1. Pathol Oncol Res 15(3):445-450
15. Junker K, Stachetzki U, Rademacher D, Linder A, Macha HN, Heinecke A, et al. (2005) HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy. Lung Cancer 48(1):59-67
16. Bai H, Wang Z, Chen K, Zhao J, Lee JJ, Wang S, et al. (2012) Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer. J Clin Oncol 30(25):3077-3083
17. Taniguchi K, Okami J, Kodama K, Higashiyama M, Kato K (2008) Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci 99(5):929-935
18. Kalikaki A, Koutsopoulos A, Trypaki M, Souglakos J, Stathopoulos E, Georgoulias V, et al. (2008) Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 99(6):923-929
19. Gomez-Roca C, Raynaud CM, Penault-Llorca F, Mercier O, Commo F, Morat L, et al. (2009) Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites. J Thorac Oncol 4(10):1212-1220
20. Chang YL, Wu CT, Shih JY, Lee YC (2011) Comparison of p53 and epidermal growth factor receptor gene status between primary tumors and lymph node metastases in non-small cell lung cancers. Ann Surg Oncol 18(2):543-550
21. Italiano A, Vandenbos FB, Otto J, Mouroux J, Fontaine D, Marcy PY, et al. (2006) Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors. Ann Oncol 17(6):981-985
22. Rao C, Hu Q, Ma J, Li J, Zhang C, Shen L, et al. (2010) Comparison of the epidermal growth factor receptor protein expression between primary non-small cell lung cancer and paired lymph node metastases: implications for targeted nuclide radiotherapy. J Exp Clin Cancer Res 29:7
23. Felip E, Rojo F, Reck M, Heller A, Klughammer B, Sala G, et al. (2008) A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy. Clin Cancer Res 14(12):3867-3874
24. De Pas T, Pelosi G, de Braud F, Veronesi G, Curigliano G, Leon ME, et al. (2004) Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. J Clin Oncol 22(24):4966-4970